Invesco Ltd. Contrafect Corp Call Options Transaction History
Invesco Ltd.
- $460 Billion
- Q2 2024
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|
Others Institutions Holding CFRX
# of Institutions
2Shares Held
49.2KCall Options Held
0Put Options Held
0About CONTRAFECT Corp
- Ticker CFRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,332,700
- Market Cap $1.18M
- Description
- ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...